EN | UA
EN | UA

Help Support

Back

Lasmiditan present a valid alternative for acute migraine treatment in urgent care

Lasmiditan present a valid alternative for acute migraine treatment in urgent care Lasmiditan present a valid alternative for acute migraine treatment in urgent care
Lasmiditan present a valid alternative for acute migraine treatment in urgent care Lasmiditan present a valid alternative for acute migraine treatment in urgent care

What's new?

Lasmiditan could be a treatment of choice for acute migraine patients with a cardiovascular risk profile due to its considerable effectiveness, safety and quality of lacking vasoconstriction.

A migraine is a painful headache and triptans are available drugs for this acute attack treatment. But because of its vasoconstrictive properties, these drugs are prohibited in patients with vascular conditions. Other limitations of these drugs include side effects like inconsistency in therapeutic action and possible non-responsiveness.

Lasmiditan, a highly selective 5-HT1F receptor agonist, acts as a novel acute anti-migraine agent which does not cause vasoconstriction.

The recent article published in Expert Opin Pharmacother evaluated the clinical efficacy and safety of oral and intravenous Lasmiditan as treatment approach for migraine. This was a review that analysed all currently available results in Phase I to III studies.

The analysis of studies showed a significant headache improvement in patients treated with Lasmiditan than placebo.  It also showed that Lasmiditan is a promising acute migraine therapy, specifically in patients at increased cardiovascular risk. The clinical efficacy of Lasmiditan proves that vasoconstriction is not essential for acute migraine therapy but also points to a well-established trigeminal contribution, to central neuronal mechanisms in migraine pathophysiology. Lasmiditan penetrates the blood-brain barrier, so CNS associated adverse events are common. But these side effects are often mild to moderate severity. The results of long-term Phase III studies will determine if these adverse events represent a limitation in clinical practice.

Source:

Expert Opin Pharmacother. 2017 Jul 27

Article:

The safety and efficacy of the 5-HT 1F receptor agonist lasmiditan in the acute treatment of migraine.

Authors:

Raffaelli B et. al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en
Try: